9 Meters Biopharma

Business model

Clinical-stage biopharmaceutical developing GI-focused rare disease treatments.

In brief

Developed vurolenatide, a GLP-1 receptor agonist candidate for short bowel syndrome, entering a category that became enormously valuable elsewhere in the pharmaceutical industry around the same time. Its drug candidate failed to demonstrate efficacy in Phase 2 clinical trials, an…

See the What Happened tab for the full account.